Caliper Life Sciences: Interview with Kevin Hrusovsky, CEO
5d 1m 3m 1y 5y 10y
CALP vs. ETF Alternatives
Thursday, Sep 82011, 7:12 AMPerkinElmer (PKI) agrees to buy Caliper Life Sciences (CALP) for $10.50 a share, a 42% premium over yesterday's closing price. The $600M deal adds "innovative molecular imaging and detection technologies" to PerkinElmer's portfolio, according to its CEO. Shares of CALP +40% premarket. |Thursday, Sep 82011, 7:12 AM| Comment!